Indonesia, Thailand, Vietnam Testing H1N1 Alternative Drug
This article was originally published in PharmAsia News
Executive Summary
Indonesia, Thailand and Vietnam have become central locations for testing alternative medicines for the H1N1 virus because an increasing number of patients have become resistant to existing treatments. In all three countries, clinical trials have begun on peramivir as an alternative antiviral to Roche's Tamiflu (oseltamivir), the main treatment against the virus, but reportedly facing resistant strains of the flu that are developing as a result to overuse. The seasonal flu virus also is reported becoming resistant to Tamiflu. (Click here for more
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.